CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

← AbbVie Inc. (ABBV) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫

AbbVie Inc. (ABBV)

Pharmaceutical Preparations · market cap $468.2B · as of 2026-07-08

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst
2026-12-15 (est.)
Phase 2
Pipeline
20
programs
Upcoming events
8
next 90d+
Dossier
Ready
cached
AbbVie Inc. (ABBV) is a large-cap pharmaceutical company with a $450B market cap, approximately 57,000 employees, and 2025 revenues of $61.2B. The company carries a heavy debt load ($55.1B net debt) offset by a diversified late-stage pipeline spanning immunology, oncology, ophthalmology, and neurology, with multiple high-importance catalysts clustered in H2 2026.
The catalyst path
  • 2026-12-15 (est.)Phase 2 · ABBV-400imp 7/10
  • 2026-12-15 (est.)Phase 3 · Lutikizumabimp 9/10
  • 2026-12-30 (est.)Phase 2 · Venetoclaximp 7/10
  • 2027-01-01 (est.)Phase 2 · Liposomal daunorubicin and cytarabineimp 7/10
  • 2027-01-15 (est.)Phase 3 · Livmoniplimabimp 9/10
  • 2027-02-01 (est.)Phase 2 · Telisotuzumab vedotinimp 7/10
  • 2027-02-15 (est.)Phase 2 · Lutikizumabimp 7/10
  • 2027-02-28 (est.)Phase 2 · Venetoclaximp 7/10
Pipeline
AssetPhaseIndication
AGN-242428Phase 2Dry Eye Disease
ABBV-8E12Phase 2Alzheimer's Disease
Erwinia asparaginasePhase 2Refractory Acute Lymphoblastic Leukemia
Risankizumab On-Body Injector (OBI)Phase 3Crohn's Disease
BIIB019 (Daclizumab High Yield Process)Phase 2Relapsing-Remitting Multiple Sclerosis
Intrathecal TriplesPhase 2Refractory Acute Lymphoblastic Leukemia
Bimatoprost (SR)Phase 3Open-Angle Glaucoma
APG777Phase 2Atopic Dermatitis
Brimonidine tartrate ophthalmic solution eye dropsPhase 2Recurrent Ovarian Cancer
ThioguaninePhase 2T-cell Acute Lymphoblastic Leukemia
ABBV-8736Phase 2Crohn's Disease
Adalimumab-800CWPhase 2IBD
Pancreatic EnzymePhase 2Short Bowel Syndrome
Prednisolone acetate ophthalmic suspension eye dropsPhase 2Recurrent Ovarian Cancer
Calaspargase pegolPhase 2T-cell Acute Lymphoblastic Leukemia
Recombinant Granulocyte Colony-Stimulating FactorPhase 2Acute Biphenotypic Leukemia
Intrathecal triple therapy (methotrexate + hydrocortisone + cytarabine)Phase 2T-cell Acute Lymphoblastic Leukemia
TrosunilimabPhase 2Crohn's Disease
Pegylated interferon (pegIFN)Phase 2Chronic Hepatitis C
etanerceptPhase 3Moderate to Severe Plaque Psoriasis
Price & technical context
3-month
+15.1%
6-month
+42.3%
12-month
+28.3%
52-wk range
$197.38–$298.06
vs 50-day MA
+7.9%
vs 200-day MA
+23.6%
Realized vol
25.2%
Max drawdown
-21.5%

Daily closes through 2026-11-16. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

Sources & data
  • SEC filings — EDGAR filings for ABBV (10-K, 10-Q, S-3, 13D/G, Form 4)
  • Clinical trials — 20 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
  • Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
  • Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.